Does the media refer more to LENZ or DRUG?

In the previous week, LENZ Therapeutics and LENZ Therapeutics both had 3 articles in the media. Bright Minds Biosciences' average media sentiment score of 1.13 beat LENZ Therapeutics' score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LENZ or SPRY?

In the previous week, ARS Pharmaceuticals had 18 more articles in the media than LENZ Therapeutics. MarketBeat recorded 21 mentions for ARS Pharmaceuticals and 3 mentions for LENZ Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.11 beat LENZ Therapeutics' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor LENZ or CTNM?

In the previous week, Contineum Therapeutics had 3 more articles in the media than LENZ Therapeutics. MarketBeat recorded 6 mentions for Contineum Therapeutics and 3 mentions for LENZ Therapeutics. Contineum Therapeutics' average media sentiment score of 0.07 beat LENZ Therapeutics' score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Contineum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CGC or LENZ?

LENZ Therapeutics has a consensus price target of $28.80, indicating a potential upside of 690.12%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 LENZ Therapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media prefer CGC or LENZ?

In the previous week, Canopy Growth had 18 more articles in the media than LENZ Therapeutics. MarketBeat recorded 21 mentions for Canopy Growth and 3 mentions for LENZ Therapeutics. Canopy Growth's average media sentiment score of 0.93 beat LENZ Therapeutics' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 14 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

LENZ Therapeutics (LENZ) Competitors

$3.58 -0.21 (-5.44%)

Closing price 03:59 PM Eastern

Extended Trading

$3.58 +0.00 (+0.03%)

As of 04:04 PM Eastern

Compare

LENZ vs. DRUG, ASMB, SPRY, CTNM, and CGC

Should you buy LENZ Therapeutics stock or one of its competitors? LENZ Therapeutics's main competitors and comparable companies include Bright Minds Biosciences (DRUG), Assembly Biosciences (ASMB), ARS Pharmaceuticals (SPRY), Contineum Therapeutics (CTNM), and Canopy Growth (CGC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does LENZ Therapeutics compare to Bright Minds Biosciences?

LENZ Therapeutics (NASDAQ:LENZ) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

LENZ Therapeutics currently has a consensus price target of $28.80, suggesting a potential upside of 690.12%. Bright Minds Biosciences has a consensus price target of $143.83, suggesting a potential upside of 189.96%. Given LENZ Therapeutics' higher possible upside, equities research analysts clearly believe LENZ Therapeutics is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Bright Minds Biosciences	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90

Bright Minds Biosciences has lower revenue, but higher earnings than LENZ Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	6.00	-$82.13M	-$4.09	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bright Minds Biosciences has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. Bright Minds Biosciences' return on equity of -12.46% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-586.74%	-53.39%	-49.14%
Bright Minds Biosciences	N/A	-12.46%	-12.30%

LENZ Therapeutics has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.21, meaning that its share price is 621% less volatile than the broader market.

In the previous week, LENZ Therapeutics and LENZ Therapeutics both had 3 articles in the media. Bright Minds Biosciences' average media sentiment score of 1.13 beat LENZ Therapeutics' score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENZ Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bright Minds Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bright Minds Biosciences beats LENZ Therapeutics on 10 of the 15 factors compared between the two stocks.

How does LENZ Therapeutics compare to Assembly Biosciences?

LENZ Therapeutics (NASDAQ:LENZ) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

LENZ Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 3.5% of Assembly Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Assembly Biosciences has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	6.00	-$82.13M	-$4.09	N/A
Assembly Biosciences	$72.30M	6.27	-$6.12M	$1.02	21.85

Assembly Biosciences has a net margin of -0.06% compared to LENZ Therapeutics' net margin of -586.74%. Assembly Biosciences' return on equity of -0.02% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-586.74%	-53.39%	-49.14%
Assembly Biosciences	-0.06%	-0.02%	-0.02%

LENZ Therapeutics currently has a consensus target price of $28.80, suggesting a potential upside of 690.12%. Assembly Biosciences has a consensus target price of $47.50, suggesting a potential upside of 113.17%. Given LENZ Therapeutics' higher possible upside, equities research analysts clearly believe LENZ Therapeutics is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, LENZ Therapeutics had 3 more articles in the media than Assembly Biosciences. MarketBeat recorded 3 mentions for LENZ Therapeutics and 0 mentions for Assembly Biosciences. LENZ Therapeutics' average media sentiment score of 0.00 equaled Assembly Biosciences'average media sentiment score.

Company	Overall Sentiment
LENZ Therapeutics	Neutral
Assembly Biosciences	Neutral

Summary

Assembly Biosciences beats LENZ Therapeutics on 11 of the 16 factors compared between the two stocks.

How does LENZ Therapeutics compare to ARS Pharmaceuticals?

LENZ Therapeutics (NASDAQ:LENZ) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, ARS Pharmaceuticals had 18 more articles in the media than LENZ Therapeutics. MarketBeat recorded 21 mentions for ARS Pharmaceuticals and 3 mentions for LENZ Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.11 beat LENZ Therapeutics' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENZ Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	19 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ARS Pharmaceuticals has a net margin of -184.24% compared to LENZ Therapeutics' net margin of -586.74%. LENZ Therapeutics' return on equity of -53.39% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-586.74%	-53.39%	-49.14%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

LENZ Therapeutics currently has a consensus target price of $28.80, suggesting a potential upside of 690.12%. ARS Pharmaceuticals has a consensus target price of $25.00, suggesting a potential upside of 494.53%. Given LENZ Therapeutics' higher probable upside, research analysts clearly believe LENZ Therapeutics is more favorable than ARS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

LENZ Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	6.00	-$82.13M	-$4.09	N/A
ARS Pharmaceuticals	$84.28M	4.96	-$171.30M	-$2.18	N/A

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

LENZ Therapeutics has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

Summary

ARS Pharmaceuticals beats LENZ Therapeutics on 8 of the 15 factors compared between the two stocks.

How does LENZ Therapeutics compare to Contineum Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

54.3% of LENZ Therapeutics shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Contineum Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. Contineum Therapeutics' return on equity of -24.73% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-586.74%	-53.39%	-49.14%
Contineum Therapeutics	N/A	-24.73%	-23.51%

LENZ Therapeutics currently has a consensus price target of $28.80, suggesting a potential upside of 690.12%. Contineum Therapeutics has a consensus price target of $22.17, suggesting a potential upside of 69.73%. Given LENZ Therapeutics' higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

LENZ Therapeutics has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

In the previous week, Contineum Therapeutics had 3 more articles in the media than LENZ Therapeutics. MarketBeat recorded 6 mentions for Contineum Therapeutics and 3 mentions for LENZ Therapeutics. Contineum Therapeutics' average media sentiment score of 0.07 beat LENZ Therapeutics' score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENZ Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Contineum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Contineum Therapeutics has higher revenue and earnings than LENZ Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	6.00	-$82.13M	-$4.09	N/A
Contineum Therapeutics	$50M	9.83	-$59.98M	-$1.73	N/A

Summary

Contineum Therapeutics beats LENZ Therapeutics on 10 of the 15 factors compared between the two stocks.

How does LENZ Therapeutics compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

3.3% of Canopy Growth shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 0.4% of Canopy Growth shares are owned by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Canopy Growth has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

In the previous week, Canopy Growth had 18 more articles in the media than LENZ Therapeutics. MarketBeat recorded 21 mentions for Canopy Growth and 3 mentions for LENZ Therapeutics. Canopy Growth's average media sentiment score of 0.93 beat LENZ Therapeutics' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	14 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LENZ Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Canopy Growth has a net margin of -65.33% compared to LENZ Therapeutics' net margin of -586.74%. Canopy Growth's return on equity of -21.91% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-65.33%	-21.91%	-14.34%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

LENZ Therapeutics has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$251.01M	1.56	-$190.29M	-$0.45	N/A
LENZ Therapeutics	$19.09M	6.00	-$82.13M	-$4.09	N/A

LENZ Therapeutics has a consensus price target of $28.80, indicating a potential upside of 690.12%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Canopy Growth and LENZ Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get LENZ Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LENZ vs. The Competition

Export

Metric	LENZ Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$112.61M	$12.22B	$7.11B	$13.24B
Dividend Yield	N/A	2.63%	2.53%	15.88%
P/E Ratio	-0.88	797.14	274.42	26.03
Price / Sales	5.90	751.87	600.72	89.51
Price / Cash	N/A	81.79	77.38	51.25
Price / Book	0.39	10.47	10.92	6.32
Net Income	-$82.13M	$2.83B	$3.50B	$361.43M
7 Day Performance	-8.34%	-1.64%	-2.07%	-1.66%
1 Month Performance	-38.21%	-5.80%	-6.32%	-3.93%
1 Year Performance	-92.58%	-3.84%	8.92%	2.82%

LENZ Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LENZ LENZ Therapeutics	2.3296 of 5 stars	$3.58 -5.4%	$28.80 +703.6%	-92.3%	$112.61M	$19.09M	N/A	152
DRUG Bright Minds Biosciences	2.5123 of 5 stars	$49.74 -3.7%	$143.83 +189.2%	-15.1%	$483.97M	N/A	N/A	25	Positive News
ASMB Assembly Biosciences	2.6096 of 5 stars	$23.48 -0.6%	$47.50 +102.3%	-6.6%	$478.05M	$72.30M	23.02	73
SPRY ARS Pharmaceuticals	1.9944 of 5 stars	$4.40 +6.5%	$25.00 +468.2%	-59.2%	$437.58M	$84.28M	N/A	200	Trending News
CTNM Contineum Therapeutics	2.3396 of 5 stars	$11.50 -9.7%	$21.00 +82.6%	+18.0%	$432.63M	$50M	N/A	51	Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LENZ) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LENZ Therapeutics (LENZ) Competitors

LENZ vs. DRUG, ASMB, SPRY, CTNM, and CGC

How does LENZ Therapeutics compare to Bright Minds Biosciences?

Summary

How does LENZ Therapeutics compare to Assembly Biosciences?

Summary

How does LENZ Therapeutics compare to ARS Pharmaceuticals?

Summary

How does LENZ Therapeutics compare to Contineum Therapeutics?

Summary

How does LENZ Therapeutics compare to Canopy Growth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LENZ vs. The Competition

LENZ Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LENZ Therapeutics (LENZ) Competitors

LENZ vs. DRUG, ASMB, SPRY, CTNM, and CGC

How does LENZ Therapeutics compare to Bright Minds Biosciences?

Do analysts rate LENZ or DRUG?

Which has higher earnings & valuation, LENZ or DRUG?

Do insiders & institutionals believe in LENZ or DRUG?

Is LENZ or DRUG more profitable?

Which has more risk and volatility, LENZ or DRUG?

Does the media refer more to LENZ or DRUG?

Summary

How does LENZ Therapeutics compare to Assembly Biosciences?

Which has more risk & volatility, LENZ or ASMB?

Do institutionals and insiders believe in LENZ or ASMB?

Which has stronger valuation & earnings, LENZ or ASMB?

Is LENZ or ASMB more profitable?

Do analysts rate LENZ or ASMB?

Does the media prefer LENZ or ASMB?

Summary

How does LENZ Therapeutics compare to ARS Pharmaceuticals?

Does the media refer more to LENZ or SPRY?

Is LENZ or SPRY more profitable?

Do analysts prefer LENZ or SPRY?

Which has better earnings & valuation, LENZ or SPRY?

Do institutionals & insiders hold more shares of LENZ or SPRY?

Which has more risk & volatility, LENZ or SPRY?

Summary

How does LENZ Therapeutics compare to Contineum Therapeutics?

Do institutionals and insiders hold more shares of LENZ or CTNM?

Is LENZ or CTNM more profitable?

Do analysts recommend LENZ or CTNM?

Which has more risk & volatility, LENZ or CTNM?

Does the media favor LENZ or CTNM?

Which has preferable valuation and earnings, LENZ or CTNM?

Summary

How does LENZ Therapeutics compare to Canopy Growth?

Do insiders & institutionals believe in CGC or LENZ?

Which has more risk & volatility, CGC or LENZ?

Does the media prefer CGC or LENZ?

Is CGC or LENZ more profitable?

Which has higher valuation & earnings, CGC or LENZ?

Do analysts rate CGC or LENZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LENZ vs. The Competition

LENZ Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools